<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215292</url>
  </required_header>
  <id_info>
    <org_study_id>38692-K</org_study_id>
    <secondary_id>U54HD012629</secondary_id>
    <nct_id>NCT01215292</nct_id>
  </id_info>
  <brief_title>ITT4 Intratesticular Hormonal Milieu in Man (ITT4)</brief_title>
  <acronym>ITT4</acronym>
  <official_title>Mechanisms of Control of the Intratesticular Hormonal Milieu in Man</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine how much male hormone, testosterone, is
      necessary to maintain sperm production in the testis. This knowledge will be used to help in
      the development of a safe male hormonal contraception.

      Specific Aims:

        1. to determine if ketoconazole plus acyline will suppress intratesticular
           testosterone(ITT) to a greater degree than acyline alone.

        2. to determine if dutasteride plus acyline will suppress intratesticular
           dihydrotestosterone (IT-DHT) to a greater degree than acyline alone.

        3. to determine if anastrazole plus acyline will suppress intratesticular estradiol(IT-E2)
           to a greater degree than acyline alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Five drugs will be used in this study: acyline, testosterone gel, ketoconazole, dutasteride,
      and anastrazole.

      Acyline suppresses luteinizing hormone (LH) and follicle stimulating hormone (FSH), which are
      hormones made by the pituitary gland in the brain, thus blocking the signal from the brain
      that causes the testes to make testosterone. Therefore, acyline blocks testosterone
      production. Men may experience some side effects from the low levels of testosterone caused
      by acyline. Acyline is an experimental drug. Over 125 men have received acyline from our lab.
      Acyline will be given by injection, and injections are formulated by subject's weight and may
      be given in multiple injections.

      Testosterone gel is given to replace testosterone level back to the normal range.
      Testosterone gel is approved for use in men with low testosterone levels.

      Ketoconazole suppresses testosterone production as well. Ketoconazole works in the adrenal
      glands to prevent testosterone production. It is approved by the U.S. FDA for treatment of
      fungal infections but for this study the use is considered investigational.

      Dutasteride blocks metabolism of testosterone into dihydrotestosterone (DHT). It is approved
      by the FDA for treatment of benign enlargement of the prostate gland, but the use is
      considered investigational in this study. Also, the dose is 5 times higher than the FDA
      approved dose.

      Anastrazole blocks metabolism of testosterone into estradiol. It is approved by the FDA for
      treatment of breast cancer but its use is considered investigational in this study.

      Participation will last approximately 2 months. The study involves a minimum of 7 visits.
      Clinic visits at Screening, Day 3 and Day 10 will take about 1-1.5 hours each. On Day 3 &amp; 10
      a fine needle aspiration of one testis will be performed. The Day 1 visit will take
      approximately 45 minutes. The Day 7 visit will take about 15 minutes. The Day 17 and Day 40
      visits will take approximately 30 minutes each. Over the course of the study, which includes
      7 separate blood draws, approximately 12 ounces (one and a half cups) of blood will be drawn.
      The acyline will be given by injection. The testosterone or placebo gel is applied to the
      skin on the chest, upper arms, and upper back. The ketoconazole, dutasteride, anastrazole, or
      placebo medication will be taken by mouth.

      Subjects randomly assigned to Group 3 will have a Cosyntropin Stimulation Test performed at
      the day 10 visit to evaluate the function of adrenal glands.

      This is NOT a trial of a male contraceptive, and the study medications will not prevent
      pregnancy. Subjects must use an acceptable form of birth control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intratesticular Testosterone (IT-T) Level</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intratesticular Dihydrotestosterone (DHT) Level</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intratesticular Androstenedione (ADD) Level</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Healthy Males</condition>
  <arm_group>
    <arm_group_label>Acyline &amp; T Gel &amp; Placebo Ketoconazole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel (T gel) 5 gm daily Days 1-10, + placebo tab PO 1x daily, Day 3-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acyline &amp; T Gel &amp; Ketoconazole 400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Days 1-10, + ketoconazole 400mg PO 1x daily, Days 3-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acyline &amp; T gel &amp; Ketoconazole 800</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + ketoconazole 800mg PO 1x daily, Days 3-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acyline &amp; T gel &amp; Dutasteride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + dutasteride 2.5 mg PO 1x daily, Days 3-10</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: anastrazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + anastrazole 1 mg PO 1x daily, Days 3-10</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyline</intervention_name>
    <description>300 mcg/kg on Day 1</description>
    <arm_group_label>Acyline &amp; T Gel &amp; Placebo Ketoconazole</arm_group_label>
    <arm_group_label>Acyline &amp; T Gel &amp; Ketoconazole 400</arm_group_label>
    <arm_group_label>Acyline &amp; T gel &amp; Ketoconazole 800</arm_group_label>
    <arm_group_label>Acyline &amp; T gel &amp; Dutasteride</arm_group_label>
    <arm_group_label>Group 5: anastrazole</arm_group_label>
    <other_name>Acyline GnRH antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone gel</intervention_name>
    <description>5 gm of 1% T Gel applied transdermally for 10 days</description>
    <arm_group_label>Acyline &amp; T Gel &amp; Placebo Ketoconazole</arm_group_label>
    <arm_group_label>Acyline &amp; T Gel &amp; Ketoconazole 400</arm_group_label>
    <arm_group_label>Acyline &amp; T gel &amp; Ketoconazole 800</arm_group_label>
    <arm_group_label>Acyline &amp; T gel &amp; Dutasteride</arm_group_label>
    <arm_group_label>Group 5: anastrazole</arm_group_label>
    <other_name>Androgel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole 400</intervention_name>
    <description>400 mg PO daily, Days 3-10</description>
    <arm_group_label>Acyline &amp; T Gel &amp; Ketoconazole 400</arm_group_label>
    <other_name>Teva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole 800</intervention_name>
    <description>800 mg PO daily, Day 3-10</description>
    <arm_group_label>Acyline &amp; T gel &amp; Ketoconazole 800</arm_group_label>
    <other_name>Teva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>2.5 mg PO daily, Day 3-10</description>
    <arm_group_label>Acyline &amp; T gel &amp; Dutasteride</arm_group_label>
    <other_name>Avodart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>1 mg PO daily, Day 3-10</description>
    <arm_group_label>Group 5: anastrazole</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ketoconazole</intervention_name>
    <description>placebo to mimic ketoconazole</description>
    <arm_group_label>Acyline &amp; T Gel &amp; Placebo Ketoconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Males age 18-50

          -  Normal serum testosterone, LH and FSH

          -  prostate-specific antigen (PSA) &lt; 4.0

          -  Agrees not to donate blood or participate in another research study during the study

          -  Informed consent

          -  Able to understand and comply with protocol requirements, instructions and
             protocol-stated restrictions

          -  In general good health based on normal screening evaluation (consisting of a medical
             history, physical exam, normal serum chemistry and hematology)

          -  Must be willing to use a reliable form of contraception during the study

        EXCLUSION CRITERIA:

          -  Poor general health, with clinically significant abnormal blood results

          -  Participation in a long-term male contraceptive study within the past three months

          -  Participation in long-term contraceptive or drug study within the past 3 months

          -  History of or current liver disease

          -  Current use of terfenadine, astemizole, cisapride, budesonide, felodipine,
             fluticasone, lovastatin, midazolam, sildenafil, or vardenafil

          -  History of testicular, prostate, or scrotal surgery/trauma or genital abnormal exam

          -  BMI &gt; 32

          -  History of sleep apnea and/or major psychiatric problems

          -  Chronic pain syndrome

          -  History of testosterone or anabolic steroid abuse currently or in the past

          -  Known bleeding disorder or current use of anticoagulation

          -  History of or current skin disorder that will interfere with testosterone gel

          -  Unwilling to adhere to protocol-stated restrictions while in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mara Y Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr</url>
    <description>Dedicated to basic and clinical research focused primarily on the male reproductive system</description>
  </link>
  <reference>
    <citation>Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990 Oct 20;336(8721):955-9.</citation>
    <PMID>1977002</PMID>
  </reference>
  <reference>
    <citation>Wu FC, Farley TM, Peregoudov A, Waites GM. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril. 1996 Mar;65(3):626-36.</citation>
    <PMID>8774299</PMID>
  </reference>
  <reference>
    <citation>Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl. 1999 May-Jun;20(3):407-14.</citation>
    <PMID>10386821</PMID>
  </reference>
  <reference>
    <citation>Zirkin BR, Santulli R, Awoniyi CA, Ewing LL. Maintenance of advanced spermatogenic cells in the adult rat testis: quantitative relationship to testosterone concentration within the testis. Endocrinology. 1989 Jun;124(6):3043-9.</citation>
    <PMID>2498065</PMID>
  </reference>
  <reference>
    <citation>Coviello AD, Matsumoto AM, Bremner WJ, Herbst KL, Amory JK, Anawalt BD, Sutton PR, Wright WW, Brown TR, Yan X, Zirkin BR, Jarow JP. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005 May;90(5):2595-602. Epub 2005 Feb 15.</citation>
    <PMID>15713727</PMID>
  </reference>
  <reference>
    <citation>Roth MY, Lin K, Amory JK, Matsumoto AM, Anawalt BD, Snyder CN, Kalhorn TF, Bremner WJ, Page ST. Serum LH correlates highly with intratesticular steroid levels in normal men. J Androl. 2010 Mar-Apr;31(2):138-45. doi: 10.2164/jandrol.109.008391. Epub 2009 Sep 24.</citation>
    <PMID>19779211</PMID>
  </reference>
  <reference>
    <citation>Trachtenberg J, Zadra J. Steroid synthesis inhibition by ketoconazole: sites of action. Clin Invest Med. 1988 Feb;11(1):1-5.</citation>
    <PMID>2966691</PMID>
  </reference>
  <reference>
    <citation>Nashan D, Knuth UA, Weidinger G, Nieschlag E. The antimycotic drug terbinafine in contrast to ketoconazole lacks acute effects on the pituitary-testicular function of healthy men: a placebo-controlled double-blind trial. Acta Endocrinol (Copenh). 1989 May;120(5):677-81.</citation>
    <PMID>2499150</PMID>
  </reference>
  <reference>
    <citation>Pont A, Graybill JR, Craven PC, Galgiani JN, Dismukes WE, Reitz RE, Stevens DA. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med. 1984 Nov;144(11):2150-3.</citation>
    <PMID>6093722</PMID>
  </reference>
  <reference>
    <citation>Van Tyle JH. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984 Nov-Dec;4(6):343-73. Review.</citation>
    <PMID>6151171</PMID>
  </reference>
  <reference>
    <citation>Soriano-Guillén L, Lahlou N, Chauvet G, Roger M, Chaussain JL, Carel JC. Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. J Clin Endocrinol Metab. 2005 Jan;90(1):147-51. Epub 2004 Nov 2.</citation>
    <PMID>15522928</PMID>
  </reference>
  <reference>
    <citation>Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002 Aug;168(2):542-5.</citation>
    <PMID>12131305</PMID>
  </reference>
  <reference>
    <citation>Herbst KL, Coviello AD, Page S, Amory JK, Anawalt BD, Bremner WJ. A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab. 2004 Dec;89(12):5959-65.</citation>
    <PMID>15579744</PMID>
  </reference>
  <results_reference>
    <citation>Roth MY, Nya-Ngatchou JJ, Lin K, Page ST, Anawalt BD, Matsumoto AM, Marck BT, Bremner WJ, Amory JK. Androgen synthesis in the gonadotropin-suppressed human testes can be markedly suppressed by ketoconazole. J Clin Endocrinol Metab. 2013 Mar;98(3):1198-206. doi: 10.1210/jc.2012-3527. Epub 2013 Jan 24.</citation>
    <PMID>23348398</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <results_first_submitted>August 20, 2013</results_first_submitted>
  <results_first_submitted_qc>December 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2014</results_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Mara Roth</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>testosterone</keyword>
  <keyword>acyline</keyword>
  <keyword>ketoconazole</keyword>
  <keyword>dutasteride</keyword>
  <keyword>anastrazole</keyword>
  <keyword>Intratesticular hormone concentration</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy men, aged 18-50 years were recruited for this study using newspaper and online advertisement, including flyers posted at the University of Washington, Seattle.</recruitment_details>
      <pre_assignment_details>Fifty-two men were screened for the study and 46 met all inclusion criteria. Six subjects withdrew from the study prior to any procedures and 40 were randomized (n=8/group. Exclusion criteria included liver disease or adrenal insufficiency, Body Mass Index &gt; 32, abnormal test results, skin conditions for gel, alcohol/drug abuse etc.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acyline &amp; T Gel &amp; Ketoconazole 400</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Days 1-10, + ketoconazole 400mg PO 1x daily, Days 3-10</description>
        </group>
        <group group_id="P2">
          <title>Acyline &amp; T Gel &amp; Dutasteride</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + dutasteride 2.5 mg PO 1x daily, Days 3-10</description>
        </group>
        <group group_id="P3">
          <title>Acyline &amp; T Gel &amp; Placebo Ketoconazole</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel (T gel) 5 gm daily Days 1-10, + placebo tab PO 1x daily, Day 3-10</description>
        </group>
        <group group_id="P4">
          <title>Acyline &amp; T Gel &amp; Ketoconazole 800</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + ketoconazole 800mg PO 1x daily, Days 3-10</description>
        </group>
        <group group_id="P5">
          <title>Group 5: Anastrazole</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + anastrazole 1 mg PO 1x daily, Days 3-10</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Fifty two men were screened for the study and 46 met all inclusion criteria. Six subject withdrew from the study prior to any procedures and 40 were randomized to treatment 8/group.</population>
      <group_list>
        <group group_id="B1">
          <title>Acyline &amp; T Gel &amp; Ketoconazole 400</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Days 1-10, + ketoconazole 400mg PO 1x daily, Days 3-10</description>
        </group>
        <group group_id="B2">
          <title>Acyline &amp; T Gel &amp; Dutasteride</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + dutasteride 2.5 mg PO 1x daily, Days 3-10</description>
        </group>
        <group group_id="B3">
          <title>Acyline &amp; T Gel &amp; Placebo Ketoconazole</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel (T gel) 5 gm daily Days 1-10, + placebo tab PO 1x daily, Day 3-10</description>
        </group>
        <group group_id="B4">
          <title>Acyline &amp; T Gel &amp; Ketoconazole 800</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + ketoconazole 800mg PO 1x daily, Days 3-10</description>
        </group>
        <group group_id="B5">
          <title>Group 5: Anastrazole</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + anastrazole 1 mg PO 1x daily, Days 3-10</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.5" lower_limit="20" upper_limit="26"/>
                    <measurement group_id="B2" value="21.5" lower_limit="20" upper_limit="24"/>
                    <measurement group_id="B3" value="24" lower_limit="21" upper_limit="35.5"/>
                    <measurement group_id="B4" value="22" lower_limit="20.5" upper_limit="25.5"/>
                    <measurement group_id="B5" value="21.5" lower_limit="20.5" upper_limit="24.5"/>
                    <measurement group_id="B6" value="22" lower_limit="20" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum FSH</title>
          <description>serum follicle-stimulating hormone</description>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" lower_limit="1.5" upper_limit="3.5"/>
                    <measurement group_id="B2" value="2.7" lower_limit="1.8" upper_limit="3.0"/>
                    <measurement group_id="B3" value="2.7" lower_limit="2.3" upper_limit="2.9"/>
                    <measurement group_id="B4" value="2.4" lower_limit="1.7" upper_limit="2.8"/>
                    <measurement group_id="B5" value="2.3" lower_limit="1.4" upper_limit="3.0"/>
                    <measurement group_id="B6" value="2.6" lower_limit="1.7" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Testosterone</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" lower_limit="5.2" upper_limit="6.2"/>
                    <measurement group_id="B2" value="5.4" lower_limit="4.4" upper_limit="6.4"/>
                    <measurement group_id="B3" value="5.2" lower_limit="4.6" upper_limit="6.3"/>
                    <measurement group_id="B4" value="5.3" lower_limit="4.7" upper_limit="6.3"/>
                    <measurement group_id="B5" value="5.2" lower_limit="4.2" upper_limit="5.8"/>
                    <measurement group_id="B6" value="5.3" lower_limit="4.8" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum DHT</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.44" lower_limit="0.35" upper_limit="0.54"/>
                    <measurement group_id="B2" value="0.5" lower_limit="0.43" upper_limit="0.89"/>
                    <measurement group_id="B3" value="0.5" lower_limit="0.37" upper_limit="0.59"/>
                    <measurement group_id="B4" value="0.44" lower_limit="0.35" upper_limit="0.53"/>
                    <measurement group_id="B5" value="0.42" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="B6" value="0.46" lower_limit="0.36" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum E2</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="16.5" upper_limit="65.8"/>
                    <measurement group_id="B2" value="24" lower_limit="20.9" upper_limit="30"/>
                    <measurement group_id="B3" value="28.3" lower_limit="21.3" upper_limit="39.6"/>
                    <measurement group_id="B4" value="39" lower_limit="23.4" upper_limit="69.4"/>
                    <measurement group_id="B5" value="39.4" lower_limit="21.1" upper_limit="51.2"/>
                    <measurement group_id="B6" value="28.3" lower_limit="20.9" upper_limit="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum ADD</title>
          <description>Serum androstenedione</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.7" lower_limit="0.57" upper_limit="1.1"/>
                    <measurement group_id="B2" value="0.75" lower_limit="0.5" upper_limit="1.1"/>
                    <measurement group_id="B3" value="0.76" lower_limit="0.52" upper_limit="1.12"/>
                    <measurement group_id="B4" value="0.69" lower_limit="0.59" upper_limit="0.76"/>
                    <measurement group_id="B5" value="0.65" lower_limit="0.6" upper_limit="0.81"/>
                    <measurement group_id="B6" value="0.67" lower_limit="0.57" upper_limit="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum DHEA</title>
          <description>serum dehydroepiandrosterone</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" lower_limit="2.7" upper_limit="7.1"/>
                    <measurement group_id="B2" value="3.9" lower_limit="3.2" upper_limit="6.6"/>
                    <measurement group_id="B3" value="4.2" lower_limit="3.3" upper_limit="6.5"/>
                    <measurement group_id="B4" value="4.6" lower_limit="2.8" upper_limit="5.9"/>
                    <measurement group_id="B5" value="3.8" lower_limit="2.8" upper_limit="4.4"/>
                    <measurement group_id="B6" value="3.9" lower_limit="2.9" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum 17-OHP</title>
          <description>serum 17-hydroxyprogesterone</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="4.2" upper_limit="7.9"/>
                    <measurement group_id="B2" value="6.1" lower_limit="5.1" upper_limit="9.1"/>
                    <measurement group_id="B3" value="7.2" lower_limit="5.9" upper_limit="9.5"/>
                    <measurement group_id="B4" value="4.8" lower_limit="4.2" upper_limit="6.7"/>
                    <measurement group_id="B5" value="6" lower_limit="4.6" upper_limit="9"/>
                    <measurement group_id="B6" value="6.1" lower_limit="4.7" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum LH</title>
          <description>serum luteinizing hormone</description>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="3.1" upper_limit="6.6"/>
                    <measurement group_id="B2" value="4.7" lower_limit="4.2" upper_limit="5.4"/>
                    <measurement group_id="B3" value="4.3" lower_limit="3.3" upper_limit="5.2"/>
                    <measurement group_id="B4" value="5.8" lower_limit="4.7" upper_limit="7.4"/>
                    <measurement group_id="B5" value="4.9" lower_limit="4.2" upper_limit="6.6"/>
                    <measurement group_id="B6" value="4.8" lower_limit="3.9" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intratesticular Testosterone (IT-T) Level</title>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acyline + Testosterone Gel + Placebo</title>
            <description>300mcg Acyline, 1% testosterone gel 5g daily + placebo</description>
          </group>
          <group group_id="O2">
            <title>Acyline + Tgel + Ketoconazole 400mg</title>
            <description>300mcg Acyline, 1% testosterone gel 5g daily + 400 mg ketoconazole</description>
          </group>
          <group group_id="O3">
            <title>Acyline + Tgel + Ketoconazole 800mg</title>
            <description>300mcg Acyline, 1% testosterone gel 5g daily + 800 mg ketoconazole</description>
          </group>
          <group group_id="O4">
            <title>Acyline &amp; TGel &amp; Dutasteride 2.5mg</title>
          </group>
          <group group_id="O5">
            <title>Acyline &amp; TGel &amp; Anastrazole 1mg</title>
          </group>
        </group_list>
        <measure>
          <title>Intratesticular Testosterone (IT-T) Level</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="8" upper_limit="21.2"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.6" upper_limit="7.2"/>
                    <measurement group_id="O3" value="1.7" lower_limit="0.9" upper_limit="4"/>
                    <measurement group_id="O4" value="18.4" lower_limit="15.3" upper_limit="24.8"/>
                    <measurement group_id="O5" value="24.0" lower_limit="17.7" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>80% power to detect 20% difference in ITT</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intratesticular Dihydrotestosterone (DHT) Level</title>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acyline + Testosterone Gel (Tgel)+ Placebo</title>
            <description>Acyline 300mcg/kg Subcutaneous (SC) (day 1) + testosterone Gel 5g daily x10 days + placebo</description>
          </group>
          <group group_id="O2">
            <title>Acyline &amp; TGel &amp; Ketoconazole 400 mg</title>
            <description>Acyline 300mcg/kg Subcutaneous (SC) (day 1) + testosterone Gel 5g daily x10 days + ketoconazole 400mg x 7 days</description>
          </group>
          <group group_id="O3">
            <title>Acyline &amp; TGel &amp; Ketoconazole 800 mg</title>
            <description>Acyline 300mcg/kg Subcutaneous (SC) (day 1) + testosterone Gel 5g daily x10 days + 800mg ketoconazole x 7 days</description>
          </group>
          <group group_id="O4">
            <title>Acyline &amp; TGel &amp; Dutasteride</title>
            <description>Acyline 300mcg/kg Subcutaneous (SC) (day 1) + testosterone Gel 5g daily x10 days + dutasteride 2.5mg x 7 days</description>
          </group>
          <group group_id="O5">
            <title>Acyline &amp; TGel &amp; Anastrazole</title>
            <description>Acyline 300mcg/kg Subcutaneous (SC) (day 1) + testosterone Gel 5g daily x10 days + Anastrazole 1mg x 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Intratesticular Dihydrotestosterone (DHT) Level</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" lower_limit="2.18" upper_limit="3.9"/>
                    <measurement group_id="O2" value="2.08" lower_limit="1.55" upper_limit="2.35"/>
                    <measurement group_id="O3" value="1.46" lower_limit="0.75" upper_limit="2.25"/>
                    <measurement group_id="O4" value="0.12" lower_limit="0.09" upper_limit="0.15"/>
                    <measurement group_id="O5" value="3.63" lower_limit="1.47" upper_limit="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intratesticular Androstenedione (ADD) Level</title>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acyline + Testosterone Gel (Tgel)+ Placebo</title>
          </group>
          <group group_id="O2">
            <title>Acyline + Tgel + Ketoconazole 400mg</title>
            <description>Acyline injection 300 mcg/kg SC (day 1) + Testosterone gel 5g + ketoconazole</description>
          </group>
          <group group_id="O3">
            <title>Acyline + Tgel + Ketoconazole 800mg</title>
            <description>Acyline injection 300 mcg/kg SC (day 1) + Testosterone gel 5g + ketoconazole</description>
          </group>
          <group group_id="O4">
            <title>Acyline &amp; TGel &amp; Dutasteride 2.5mg</title>
          </group>
          <group group_id="O5">
            <title>Acyline &amp; TGel &amp; Anastrazole 1mg</title>
          </group>
        </group_list>
        <measure>
          <title>Intratesticular Androstenedione (ADD) Level</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".87" lower_limit=".67" upper_limit="2.1"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.3" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.12" lower_limit="0.1" upper_limit="0.5"/>
                    <measurement group_id="O4" value="1.7" lower_limit="1.14" upper_limit="3.0"/>
                    <measurement group_id="O5" value="3.6" lower_limit="1.6" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Acyline &amp; T Gel &amp; Ketoconazole 400</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Days 1-10, + ketoconazole 400mg PO 1x daily, Days 3-10</description>
        </group>
        <group group_id="E2">
          <title>Acyline &amp; T Gel &amp; Dutasteride</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + dutasteride 2.5 mg PO 1x daily, Days 3-10</description>
        </group>
        <group group_id="E3">
          <title>Acyline &amp; T Gel &amp; Placebo Ketoconazole</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel (T gel) 5 gm daily Days 1-10, + placebo tab PO 1x daily, Day 3-10</description>
        </group>
        <group group_id="E4">
          <title>Acyline &amp; T Gel &amp; Ketoconazole 800</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + ketoconazole 800mg PO 1x daily, Days 3-10</description>
        </group>
        <group group_id="E5">
          <title>Group 5: Anastrazole</title>
          <description>Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + anastrazole 1 mg PO 1x daily, Days 3-10</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular hematoma and hematocele</sub_title>
                <description>Development of testicular hematoma and scrotal hematocele after second testicular aspiration on day 10. Underwent operative evacuation of hematocele and cauterization of superficial testicular vessel. Follow-up ultrasound showed complete recovery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased libido</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain at spermatic cord/at scrotum</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>platar fascitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Finger laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Change in mood/irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergies</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritus/rash</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>abdomenal ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mara Roth, MD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-221-0519</phone>
      <email>mylang@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

